Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study

Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grzegorz Grześk, Wioleta Stolarek, Michał Kasprzak, Elżbieta Grześk, Daniel Rogowicz, Michał Wiciński, Marek Krzyżanowski
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	carbamazepine antiepileptic drugs carbamazepine plasma levels epilepsy therapeutic drug monitoring Medicine R
Acceso en línea:	https://doaj.org/article/087f8f7936244ffe9e332b847304279c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:087f8f7936244ffe9e332b847304279c
record_format	dspace
spelling	oai:doaj.org-article:087f8f7936244ffe9e332b847304279c2021-11-25T18:02:25ZTherapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study10.3390/jcm102253962077-0383https://doaj.org/article/087f8f7936244ffe9e332b847304279c2021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5396https://doaj.org/toc/2077-0383Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011. The method used for the determination of the CBZ concentration was fluorescence polarization immunoassay (FPIA) performed using an Abbott GmbH TDx automatic analyzer, with the therapeutic range for carbamazepine being 4–12 µg/mL. Results: The therapeutic range was observed more often in patients between 3 and 17 years of age compared with the population ≥18 years of age (73.5% vs. 68.8%). The therapeutic level was exceeded less frequently in the population between 3 and 17 years of age despite them being given a significantly higher dose per kilogram of body weight than in the population ≥18 years of age (13.64 mg/kg vs. 10.43 mg/kg, <i>p</i> < 0.0001). Patients ≥18 years of age were statistically significantly more likely to be in the group with a suspected drug overdose (73.9% vs. 26.1%), and suicide attempts only occurred in elderly patients (100.0% vs. 0.0%, <i>p</i> = 0.003). Conclusion: The results of the TDM of CBZ showed that only 71% of all samples were at the therapeutic level. To ensure the maximum efficacy and safety of the therapy, it is necessary to monitor the concentration of CBZ regardless of sex and age.Grzegorz GrześkWioleta StolarekMichał KasprzakElżbieta GrześkDaniel RogowiczMichał WicińskiMarek KrzyżanowskiMDPI AGarticlecarbamazepineantiepileptic drugscarbamazepine plasma levelsepilepsytherapeutic drug monitoringMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5396, p 5396 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	carbamazepine antiepileptic drugs carbamazepine plasma levels epilepsy therapeutic drug monitoring Medicine R
spellingShingle	carbamazepine antiepileptic drugs carbamazepine plasma levels epilepsy therapeutic drug monitoring Medicine R Grzegorz Grześk Wioleta Stolarek Michał Kasprzak Elżbieta Grześk Daniel Rogowicz Michał Wiciński Marek Krzyżanowski Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
description	Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011. The method used for the determination of the CBZ concentration was fluorescence polarization immunoassay (FPIA) performed using an Abbott GmbH TDx automatic analyzer, with the therapeutic range for carbamazepine being 4–12 µg/mL. Results: The therapeutic range was observed more often in patients between 3 and 17 years of age compared with the population ≥18 years of age (73.5% vs. 68.8%). The therapeutic level was exceeded less frequently in the population between 3 and 17 years of age despite them being given a significantly higher dose per kilogram of body weight than in the population ≥18 years of age (13.64 mg/kg vs. 10.43 mg/kg, <i>p</i> < 0.0001). Patients ≥18 years of age were statistically significantly more likely to be in the group with a suspected drug overdose (73.9% vs. 26.1%), and suicide attempts only occurred in elderly patients (100.0% vs. 0.0%, <i>p</i> = 0.003). Conclusion: The results of the TDM of CBZ showed that only 71% of all samples were at the therapeutic level. To ensure the maximum efficacy and safety of the therapy, it is necessary to monitor the concentration of CBZ regardless of sex and age.
format	article
author	Grzegorz Grześk Wioleta Stolarek Michał Kasprzak Elżbieta Grześk Daniel Rogowicz Michał Wiciński Marek Krzyżanowski
author_facet	Grzegorz Grześk Wioleta Stolarek Michał Kasprzak Elżbieta Grześk Daniel Rogowicz Michał Wiciński Marek Krzyżanowski
author_sort	Grzegorz Grześk
title	Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
title_short	Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
title_full	Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
title_fullStr	Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
title_full_unstemmed	Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
title_sort	therapeutic drug monitoring of carbamazepine: a 20-year observational study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/087f8f7936244ffe9e332b847304279c
work_keys_str_mv	AT grzegorzgrzesk therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT wioletastolarek therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT michałkasprzak therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT elzbietagrzesk therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT danielrogowicz therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT michałwicinski therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy AT marekkrzyzanowski therapeuticdrugmonitoringofcarbamazepinea20yearobservationalstudy
_version_	1718411660762284032

Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study

Ejemplares similares